Genetic instruments in distinct LDL-related genes yield concordant estimates of LDL's effect on cardiovascular risk
3 events · 1 assessment · 1 decision
Structured and assessed
First pass. Kept the claim atomic: it is a single, reusable empirical observation about the drug-target MR literature. Candidate dependencies (e.g. that distinct genes lower LDL via different mechanisms, or the specific per-gene ORs) are either uncontested setup or source-specific facts that belong in prose, not as nodes (§6); no genuine disputable subclaim underlies it. Neighboring claims exist (PCSK9/HMGCR concordance feeds the 'no pleiotropy' parent 05c19437, which already lists this as a supporting subclaim), but no additional child needed linking. Set importance 0.32 (notable, low contestation 0.12): consequential as support for the causality/pleiotropy debate but the concordance data itself is robust and undisputed. Assessed verified (conf 0.9, credence 0.94) on primary sources: Ference NEJM 2016 (PCSK9 vs HMGCR OR 0.84 vs 0.84 per 10 mg/dL), the NPC1L1/HMGCR 2×2 factorial MR (OR 0.952 vs 0.947), and the ACLY MR (NEJM 2019), plus multi-gene drug-target replications. Canonical form is neutral and ~15 words; kept as is.
Assessed Verified
verdict confidence 0.90 · credence 0.94
Drug-target Mendelian randomization studies consistently find that genetic variants in different LDL-lowering genes, which lower LDL cholesterol by entirely different biological mechanisms, produce closely matching estimates of LDL's per-unit effect on coronary risk. The clearest demonstration compared variants near PCSK9 and HMGCR (the statin target): scaled to the same LDL reduction, the two genetic scores had nearly identical associations with coronary heart disease. A factorial study of NPC1L1 (the ezetimibe target) and HMGCR variants likewise found near-identical per-unit effects, and later analyses of ACLY and LDLR variants fall on the same line. This convergence across mechanistically distinct instruments is a robust and repeatedly replicated feature of the literature. The finding matters because concordance across genes that share only their effect on LDL is difficult to explain by gene-specific off-target (pleiotropic) effects, which is why it is treated as strong evidence that the genetic signal acts through LDL itself. The concordance observation as such is not seriously disputed; disagreement in this area concerns how far the causal interpretation can be pushed, not whether the estimates from distinct LDL genes agree.
Claim entered the graph